RT Journal Article
SR Electronic
T1 A distinct class of pan-cancer susceptibility genes revealed by alternative polyadenylation transcriptome-wide association study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.28.23286554
DO 10.1101/2023.02.28.23286554
A1 Chen, Hui
A1 Wang, Zeyang
A1 Wang, Jia
A1 Chen, Wenyan
A1 Ma, Xuelian
A1 Zou, Xudong
A1 Plass, Mireya
A1 Lian, Cheng
A1 Ni, Ting
A1 Wei, Gong-Hong
A1 Li, Wei
A1 Deng, Lin
A1 Li, Lei
YR 2023
UL http://medrxiv.org/content/early/2023/03/01/2023.02.28.23286554.abstract
AB Alternative polyadenylation (APA) plays an important role in cancer initiation and progression; however, current genome- and transcriptome-wide association studies (GWAS and TWAS, respectively) mostly ignore APA when identifying putative cancer susceptibility genes. Here, we performed a pan-cancer 3′untranslated region (UTR) APA TWAS (3′aTWAS) by integrating 80 well-powered (n>50,000) GWAS datasets across 23 major cancer types with APA quantification from 17,330 RNA sequencing samples across 49 tissue types and 949 individuals. We found that genetic variants associated with APA represent around 24.4% of cancer GWAS variants and are more likely to be causal variants explaining a large portion of cancer heritability. We further identified 413 significant APA-linked cancer susceptibility genes. Of these, 77.4% have been overlooked by traditional expression- and splicing-studies, given that APA may regulate translation, protein localization, and protein–protein interactions independent of the expression level of the genes or splicing isoforms. As proof of principle validation, modulation of four novel APA-linked breast-cancer susceptibility genes significantly altered cancer cell proliferation. Our study highlights the significant role of APA in discovering new cancer susceptibility genes and provides a strong foundational framework for enhancing our understanding of the etiology underlying human cancers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Key Research and Development Program of China (no. 2022YFA1302800) to L.D., National Natural Science Foundation of China (no. 32100533) and Open grant funds from Shenzhen Bay Laboratory (no. SZBL2021080601001) to L.L. National Natural Science Foundation of China (no. 32270779) to L.D..Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Raw whole transcriptome and genome sequencing data from the Genotype-Tissue Expression (GTEx) project are available via the database of Genotypes and Phenotypes (dbGaP), under the accession number: phs000424.v8.p2. All processed GTEx data are available via the GTEx portal((http://gtexportal.org/). GWAS summary statistics are from NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/), UK Biobank GWAS, http://www.nealelab.is/uk-biobank/), Finn Gen(https://www.finngen.fi/en) and JENGER(http://jenger.riken.jp). The details, including accession numbers, of GWAS summary statistics used in this study are listed in Supplementary Table 1.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRaw whole transcriptome and genome sequencing data from the Genotype-Tissue Expression (GTEx) project are available via the database of Genotypes and Phenotypes (dbGaP), under the accession number: phs000424.v8.p260. All processed GTEx data are available via the GTEx portal((http://gtexportal.org/). GWAS summary statistics are from NHGRI-EBI GWAS catalog (https://www.ebi.ac.uk/gwas/), UK Biobank GWAS, http://www.nealelab.is/uk-biobank/), Finn Gen(https://www.finngen.fi/en) and JENGER(http://jenger.riken.jp). The details, including accession numbers, of GWAS summary statistics used in this study are listed in Supplementary Table 1. 1000 Genomes Project Reference for LDSC, https://data.broadinstitute.org/alkesgroup/LDSCORE/1000G_Phase3_plinkfiles.tgz; 1000 Genomes Project Reference with regression weights for LDSC, https://data.broadinstitute.org/alkesgroup/LDSCORE/1000G_Phase3_weights_hm3_no_MHC.tgz). All significant 3′aTWAS genes in cancer are available at Supplementary Table 6. The expression and splicing TWAS models for GTEx v8 are publicly available at PredictDB (https://predictdb.org/).